Up 79% in a month, is Angle a penny stock worth considering?

Angle (LON:AGL) is a penny stock that exploded higher over the past few weeks. What has sent this share rocketing?

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The words ‘roller-coaster ride’ get thrown around a lot when talking about shares. But there are roller coasters and then there is Angle (LSE: AGL). This penny stock is more like a bucking bronco!

In early 2024, it surged more than 100% in a single day, then lost half its value in a month. Now the share price has risen by 79% in four weeks to sit at 21p. But it’s still 78% lower than it was just two years ago.

I have a very small position in the stock. Should I add to it?

What does the firm do?

AIM-listed Angle is a cancer diagnostic company that has developed a potentially groundbreaking technology called the Parsortix system. This provides a unique approach to capturing and analysing circulating tumour cells (CTCs) from the blood of cancer patients.

The system appears to represent a significant advancement in liquid biopsy (a blood test that allows the detection and analysis of cancer cells or fragments of the tumor’s DNA).

Cancer treatment often relies on understanding the specific characteristics of a patient’s tumour. Yet these can change over time. So the ability to capture CTCs and analyse them effectively allows the monitoring of cancer patients’ responses to treatments.

This is potentially a great development for patients and outcomes. But how will the company benefit?

Why is the stock up?

Well, in April, Angle announced a deal with FTSE 100 pharma giant AstraZeneca to develop a CTC test for DNA damage. The six-month development phase is worth an initial £150,000 to the firm.

Then in May, it signed another deal with Astra to develop a new CTC assay to detect androgen receptor (AR) status in prostate cancer patients.

Using Angle’s technology, clinicians can assess the effectiveness of prostate cancer therapies while a patient’s treatment is ongoing.

These were the catalysts for the recent share price explosion. The company is seemingly on the road to commercial lift-off.

Should I buy more shares?

Now, while this could eventually be a very lucrative market opportunity, investors should be realistic about the near term.

The two deals announced so far with AstraZeneca are collectively worth less than £1m. Meanwhile, the development of the AR assay isn’t expected to be completed before 2025.

Moreover, the company will probably need to issue more shares to raise cash in the next couple of years, which could cause volatility.

Today, the firm is hardly generating any revenue, yet has a market cap of £55m. This means the stock is trading on a price-to-sales (P/S) ratio of 32.

Clearly, the firm is being valued on its high future potential. But with its groundbreaking technology being validated with blue-chip partnerships, I do expect much large contracts to be announced moving forward.

If this does happen, then the share price could keep heading higher. But as things stand, this is a speculative and high-risk stock. It is only suitable for investors with a high risk tolerance.

On balance, I’m going to stick with my holding. If the stock reaches its potential and flies higher, a small position is all I will need. If it crashes, then that will be all I want.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Angle Plc and AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »

Investing Articles

Down 47% in 5 years, is the IAG share price due a bounce?

Many companies in the travel sector have seen fierce rallies since 2020. But with the IAG share price still down…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Despite its drop, I reckon this is one of the best FTSE 100 stocks to buy and hold!

The FTSE 100 has been climbing in 2024 but this favourite of our writer's has been falling. Despite this, she’s…

Read more »

Investing Articles

AI stocks vs EV shares; which is the best sector for me to invest in?

Jon Smith considers the recent rally in AI stocks and weighs up whether to allocate more money there versus EV…

Read more »

A graph made of neon tubes in a room
Investing Articles

Do Greggs shares have even more growth ahead?

Greggs shares have seen some solid growth in the last few months, as the economy shows positive signs. But is…

Read more »

Investing For Beginners

How I’d aim to grow my Stocks & Shares ISA from £20k to £1m

Jon Smith explains how diversification and focusing on sectors for the future can help grow his Stocks and Shares ISA.

Read more »